Clinical significance of plasma VEGF value in ischemic stroke - research for biomarkers in ischemic stroke (REBIOS) study by Ryu Matsuo et al.
Matsuo et al. BMC Neurology 2013, 13:32
http://www.biomedcentral.com/1471-2377/13/32RESEARCH ARTICLE Open AccessClinical significance of plasma VEGF value in
ischemic stroke - research for biomarkers in
ischemic stroke (REBIOS) study
Ryu Matsuo1*†, Tetsuro Ago1*†, Masahiro Kamouchi1, Junya Kuroda1, Takahiro Kuwashiro1, Jun Hata2,
Hiroshi Sugimori1, Kenji Fukuda4, Seiji Gotoh2, Noriko Makihara3, Masayo Fukuhara2, Hideto Awano5,
Tetsu Isomura5, Kazuo Suzuki5, Masahiro Yasaka3, Yasushi Okada3, Yutaka Kiyohara2 and Takanari Kitazono1Abstract
Background: Vascular endothelial growth factor (VEGF) is a well-known molecule mediating neuronal survival and
angiogenesis. However, its clinical significance in ischemic stroke is still controversial. The goal of this study was to
examine the temporal profile of plasma VEGF value and its clinical significance in ischemic stroke with taking its
subtypes into consideration.
Methods: We prospectively enrolled 171 patients with ischemic stroke and age- and gender-matched healthy
subjects. The stroke patients were divided into 4 subtypes: atherothrombotic infarction (ATBI, n = 34), lacunar
infarction (LAC, n = 45), cardioembolic infarction (CE, n = 49) and other types (OT, n = 43). Plasma VEGF values were
measured as a part of multiplex immunoassay (Human MAP v1.6) and we obtained clinical information at 5 time
points (days 0, 3, 7, 14 and 90) after the stroke onset.
Results: Plasma VEGF values were significantly higher in all stroke subtypes but OT than those in the controls
throughout 90 days after stroke onset. There was no significant difference in the average VEGF values among ATBI,
LAC, and CE. VEGF values were positively associated with neurological severity in CE patients, while a negative
association was found in ATBI patients. After adjustment for possible confounding factors, plasma VEGF value was
an independent predictor of poor functional outcome in CE patients.
Conclusions: Although plasma VEGF value increases immediately after the stroke onset equally in all stroke
subtypes, its significance in functional outcome may be different among the stroke subtypes.
Keywords: Brain infarction, Vascular endothelial growth factor (VEGF), National Institute of health stroke scale
(NIHSS), Functional outcome, Modified rankin scale (mRS)Background
Stroke is a leading cause of functional dependence and
death [1]. It is important to prevent the occurrence of
stroke and to perform immediate thrombolytic therapies
when ischemic stroke occurs. The thrombolytic therapy
using recombinant tissue plasminogen activator (rtPA) is
becoming popular; however, the narrow therapeutic time
window often limits the use of rtPA for patients with* Correspondence: rymatsuo@intmed2.med.kyushu-u.ac.jp;
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reproduction in any medium, provided the orischemic stroke [2]. Thus, we should make efforts to mi-
nimize neurological deterioration in the acute phase and
to induce efficient neurological recovery in the sub-
acute to chronic phase.
Vascular endothelial growth factor (VEGF), discovered
in 1983 as a vascular permeability factor, is a key protein
inducing angiogenesis in health and disease [3-5]. VEGF
binds to the receptor tyrosine kinases VEGFR-1 (Flt-1)
and VEGFR-2 (KDR/Flk-1) and mediates intracellular
signaling leading to cell growth and survival in various
cells. In the brain, VEGF is abundantly produced from
neurons and vascular cells and acts on themselves, thereby
playing an important role in mediating neuronal survivalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Matsuo et al. BMC Neurology 2013, 13:32 Page 2 of 8
http://www.biomedcentral.com/1471-2377/13/32and angiogenesis [6]. Thus, one may expect that VEGF
must exert beneficial effects in ischemic stroke. The ex-
pression of VEGF is transcriptionally upregulated by
hypoxia-inducible factor in response to hypoxia. Consis-
tently, in experimental ischemic stroke models, which
mimic cardioembolic stroke in humans, the expression of
VEGF and its receptor Flt-1 is upregulated in neurons and
vascular cells in peri-infarct areas [7]. However, in these
models, the suppression of the VEGF-Flt-1 signaling ra-
ther brings about beneficial effects on the brain [3]. It may
be because VEGF induces endothelial proliferation and in-
creases endothelial permeability leading to the breakdown
of the blood–brain barrier [8,9]. Thus, the overall effect of
VEGF on the brain in ischemic stroke is complicated and
may be determined by ischemic strength, duration, and
the presence of collateral circulation.
Brain infarction is classified into at least 4 different
stroke subtypes, atherothrombotic infarction (ATBI), car-
dioembolic infarction (CE), lacunar infarction (LAC), and
other types (OT). Ischemic strength, duration, and the
presence of collateral circulation are different among the
stroke subtypes. It has been reported that serum VEGF is
increased in human stroke patients [10,11]. However,
there have been no reports thus far examining in detail
the difference of the clinical significance of VEGF among
stroke subtypes. We hypothesized that due to the hetero-
geneity of ischemic stroke, the clinical significance of
plasma VEGF may be different among stroke subtypes. In
the present study, we examined the temporal profile of
plasma VEGF value for 3 months after the stroke onset
and the association of plasma VEGF with the neurological
outcome in ischemic stroke, with taking its subtypes into
consideration.Methods
Ethics
The study protocol and all subsequent amendments are
approved by the leading ethic committee of the Kyushu
University Hospital (Kyushu University Institutional
Review Board for Clinical Research, reference number
#20-30, date of approval 9/26/2008) and the local ethics
committees of the participating centers, National Hospital
Organization Kyushu Medical Center (Kyushu Medical
Center Institutional Review Board for Clinical Research,
reference number # 07–38, date of approval 8/26/2007)
and St Mary’s Hospital (St Mary’s Hospital Institutional
Review Board for Clinical Research, date of approval 3/11/
2008). The study is performed in accordance with the
Declaration of Helsinki and its subsequent amendments,
as well as the guidelines of Good Clinical Practice. The
study is registered at the Fukuoka Stroke Registry (FSR), a
multicenter observational study for acute brain infarction
in Japan [12,13]. The registration number is #22-164.Study subjects
We recruited 171 patients with ischemic stroke who were
hospitalized at Kyushu University Hospital, National
Hospital Organization Kyushu Medical Center or St.
Mary’s Hospital in Japan. On admission, the objectives,
study design, risks and benefits were explained in de-
tail to each patient or surrogate family members and
written informed consent was obtained. Patients who
consented to the study were prospectively enrolled and
followed up to 3 months after the onset. Inclusion cri-
teria were as follows: 1) ischemic stroke hospitalized
within 24 hours after the onset, 2) definite diagnosis
of stroke subtype. We excluded the patients who had
severe complication, such as pneumonia or urinary
tract infection, during the observational period.
An equal number of age- and gender-matched controls
without a history of cardiovascular diseases, such as
stroke, coronary heart diseases and atrial fibrillation,
were enrolled as healthy subjects from the participants
in the Hisayama Study, a worldwide well-known cohort
study [14,15].Diagnosis of ischemic stroke and subtype
Stroke was defined as a sudden onset of focal neuro-
logical deficit persisting for more than 24 hours. The
diagnosis of brain infarction was confirmed by brain im-
aging, including CT and MRI, in all patients. On the
basis of the TOAST classification with minor modifica-
tion, [16] we classified stroke patients into four catego-
ries (subtypes), i.e. atherothrombotic infarction (ATBI,
n = 34), lacunar infarction (LAC, n = 45), cardioembolic
infarction (CE, n = 49), and other type of brain infarction
(OT, n = 43). We combined “Stroke of other determined
etiology” and “stroke of undetermined etiology” into OT
in this study.Data sampling
Peripheral venous blood samples were collected from
patients at five time points after the onset, days 0 (on
admission), 3, 7, 14, and 90. Blood samples were mixed
in an EDTA-containing tube, and were centrifuged at
1,400 × g for 10 min at 4 degrees immediately after they
were drawn. The resultant plasma samples were frozen
at 80 degrees below zero within 10 minutes. They were
stored for about two weeks until the measurement of
VEGF. For healthy control subjects, blood samples were
obtained at one point at the enrollment. Plasma VEGF
values were measured using the Human Multi-Analyte
Profile (MAP) v1.6 provided by Rules-Based Medicine,
Inc. (RBM, TX, USA) [17]. A complete list of the ana-
lytes is available at http://www.myriadrbm.com/products-
services/humanmap-services/.
Table 1 Background characteristics of controls and stroke
cases
Controls Cases p-Value
n = 171 n = 171
Age, years, mean ± SD 68.1 ± 10.1 68.3 ± 10.1 0.84
Male, n (%) 115 (67.3) 115 (67.3) 1.00
Risk factors
Hypertension, n (%) 72 (42.1) 132 (77.2) <0.001
Dyslipidemia, n (%) 88 (51.5) 100 (58.5) 0.19
Diabetes, n (%) 11 (6.4) 54 (31.6) <0.001
Atrial fibrillation, n (%) 0 (0) 59 (34.5) <0.001
Smoking, n (%) 36 (21.1) 96 (56.1) <0.001
Alcohol, n (%) 98 (57.3) 75 (43.9) 0.01
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Hypertension was defined as systolic blood pressure ≥
140 mmHg and/or diastolic pressure ≥ 90 mmHg or as
current treatment with antihypertensive drugs during
the chronic stage of stroke or at enrollment for control
subjects. Diabetes mellitus was determined by either a
75 g oral glucose tolerance test according to the diagnostic
criteria of the World Health Organization in 1998, [18]
casual blood glucose levels (≥ 11.1 mmol/L (200 mg/dL)),
or a medical history of diabetes. Dyslipidemia was defined
as either a cholesterol level ≥ 5.7 mmol/L (220 mg/dL), a
low-density lipoprotein-cholesterol level ≥ 3.62 mmol/L
(140 mg/dL), a high-density lipoprotein-cholesterol le-
vel < 1.03 mmol/L (40 mg/dL) or current treatment with a
cholesterol-lowering drug. Atrial fibrillation was diag-
nosed based on electrocardiographic findings or medical
history. Smoking was defined as having a previous or
current smoking habit. Alcohol intake was defined as ha-
ving a previous or current consumption including occa-
sional drinking.
Evaluation of neurological severity and functional outcome
In analyses regarding neurological severity, patients were
divided into tertiles (mild, moderate, and severe) in each
stroke subtype, according to the National Institute of
Health Stroke Scale (NIHSS). Functional outcome was
evaluated by the modified Rankin Scale (mRS). Func-
tional outcome was defined as poor (mRS score > 2) or
good (mRS score ≤ 2). NIHSS was assessed at day 0 and
14, and mRS at day 14 and 90.
Statistical analyses
JMP software ver.8.0 (SAS Institute, Cary, NC) was used
to perform all statistical analyses. In univariate analyses,
categorical variables were compared by the χ2 test, con-
tinuous variables by an unpaired Student t test or multiple
comparisons as appropriate. In multivariate analyses, we
performed logistic regression analyses with adjustment for
confounding factors. P < 0.05 was considered significant.
Results
Background characteristics of control and stroke patients
Background characteristics of control subjects and stroke
patients are summarized in Table 1 and Additional file 1:
Table S1. The prevalence of hypertension, diabetes mel-
litus, atrial fibrillation and smoking were significantly
higher in the stroke patients than the control. In contrast,
alcohol intake was significantly higher in the control.
Plasma VEGF values are increased immediately after
stroke onset in all subtypes
Plasma VEGF values at day 0 were significantly higher in
the patients (569 ± 13 pg/mL) than in the control (471 ±
13 pg/mL) (p < 0.001) (Figure 1A). A multivariate analysisadjusting for possible confounding factors demonstrated
that plasma VEGF values were independently associated
with brain infarction (OR 1.003 [1.001-1.005], p = 0.003).
We investigated whether stroke-related risk factors or pre-
treatment affected plasma VEGF values. There was no as-
sociation between the value of VEGF and stroke-related
risk factors or pretreatment therapies, such as statins.
For example, plasma VEGF values did not differ between
in ischemic stroke patients with pretreatment of statin
(n = 31, 611 ± 35 pg/mL) and those without (n = 140,
561 ± 17 pg/mL) (p = 0.20).
We classified stroke patients into 4 groups: ATBI
(n = 34, 19.9%), LAC (n = 45, 26.3%), CE (n = 49, 28.7%),
and OT (n = 43, 25.1%). Plasma VEGF values at day 0
were significantly higher in all stroke subtypes but OT
(ATBI 593 ± 29 pg/mL, p = 0.016; LAC 584 ± 26 pg/mL,
p = 0.003; CE 561 ± 24 pg/mL, p = 0.03; and OT 543 ±
30 pg/mL, p = 0.11) than those in the corresponding con-
trols. There was no significant difference in the VEGF
values among ATBI, LAC, and CE (Figure 1B).
Temporal profile of plasma VEGF values in each stroke
subtype
Temporal profile of plasma VEGF values in each stroke
subtype from day 0 to day 90 is shown in Figure 2A
(ATBI), 2B (LAC), 2C (CE) and 2D (OT). The increases
in plasma VEGF values lasted for 90 days after the onset
in all subtypes.
Association between plasma VEGF value and neurological
severity
We next examined the association between plasma VEGF
values and neurological severity on admission in each
stroke subtype. The median NIHSS on admission was 4
(interquartile range (IQR): 2–8) in ATBI, 3 (IQR: 1–4) in
LAC, 7 (IQR: 3–12) in CE and 4 (IQR: 2–6) in OT pa-
tients. We divided stroke patients into 3 groups in each
subtype according to neurological severity as assessed by
Figure 1 Plasma VEGF values at day 0 after ischemic stroke. Plasma VEGF levels at day 0 in stroke patients (PT, n = 171) and controls
(CON, n = 171) (A), and those in each stroke subtype (B): atherothrombotic infarction (ATBI, n = 34), lacunar infarction (LAC, n = 45), cardioembolic
infarction (CE, n = 49) and other type infarction (OT, n = 43). Data are expressed as mean ± SEM. *P < 0.01 vs. control, #P < 0.05 vs. control.
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each stroke subtype were as follows; in ATBI (mild 0–2;
moderate 3–5; and severe 6–24); in LAC (mild 0–1; mo-
derate 2–3; and severe 4–9); in CE (mild 0–3; moderate
4–9; and severe 10–25); and in OT (mild 0–2; moderate
3–4; and severe 5–31) (Figure 3 and Additional file 1:
Table S2). Plasma VEGF values at day 0 were higher in the
severe group in CE patients (Figure 3C), while they were
higher in the mild group in ATBI patients (Figure 3A),
although both failed to reach statistical significance. There
was no association between VEGF values and neurological
severity in LAC and OT patients (Figure 3B, Figure 3D).
We also divided stroke patients into 3 groups at day 14
(Figure 3 and Additional file 1: Table S2). At day 14, the
similar association was found in both CE (Figure 3G)
and ATBI (Figure 3E), with statistical significance inFigure 2 Temporal profile of plasma VEGF levels in each stroke subty
Data are expressed as mean ± SEM. *P < 0.01 vs. control, #P < 0.05 vs. controCE (Figure 3G). There was no association between plasma
VEGF values and neurological severity in LAC and OT
patients (Figure 3F, Figure 3H).
Association between plasma VEGF value and functional
outcome
We further examined the impact of plasma VEGF values
on functional outcome at day 90 in each stroke subtype.
VEGF values at day 0 were significantly higher in the
poor outcome group (mRS > 2; 681 ± 40 pg/mL) than in
the good outcome group (mRS ≤ 2; 496 ± 31 pg/mL) in CE
patients (p < 0.001; Figure 4C). In contrast, VEGF values
tended to be higher in the good outcome group (619 ± 32
pg/mL) than in the poor outcome group (553 ± 43 pg/mL)
in ATBI patients (p = 0.23; Figure 4A). There was not sig-
nificant association between VEGF values and functionalpe from day 0 to day 90, A) ATBI, B) LAC, C) CE, D) OT.
l.
Figure 3 Association between plasma VEGF values and neurological severity. Association between VEGF values and neurological severity
at day 0 in each stroke subtype, A) ATBI (mild 0–2; moderate 3–5; and severe 6–24); B) LAC (mild 0–1; moderate 2–3; and severe 4–9); C) CE
(mild 0–3; moderate 4–9; and severe 10–25); D) OT (mild 0–2; moderate 3–4; and severe 5–31), and at day 14 in each stroke subtype, E) ATBI
(mild 0–1; moderate 2–5; and severe 6–17); F) LAC (mild 0; moderate 1; and severe 2–6); G) CE (mild 0; moderate 1–3; and severe 4–24);
H) OT (mild 0; moderate 1–2; and severe 3–24). Data are expressed as mean ± SEM. *P < 0.05 vs. mild group.
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767 ± 134 pg/mL; p = 0.17; Figure 4B) and in OT patients
(good: 544 ± 37 pg/mL vs poor: 537 ± 67 pg/mL; p = 0.92;
Figure 4D).
Finally, we examined whether plasma VEGF value could
be a predictor of functional outcome. We presented the
data only of ATBI and CE, because there were only fewpatients with poor prognosis in LAC (n = 3) and there was
no difference in plasma VEGF values between good prog-
nosis group and poor one in OT (p = 0.92). A multivariate
logistic regression analysis, adjusting for age, gender, hy-
pertension, diabetes mellitus, neurological severity (NIHSS
at day 0) and thrombolytic therapy revealed that the plasma
VEGF value at day 0 could predict poor functional
Figure 4 Association between VEGF values and functional outcome. VEGF values and functional outcome in each stroke subtype are shown
in A) ATBI, B) LAC, C) CE, and D) OT. Data are expressed as mean ± SEM. *P < 0.05 vs. good group.
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(95% confidence intervals: 1.78-11.95) per 100 pg/mL in-
crease in VEGF (p < 0.001; Figure 5A). Similarly, higher
VEGF values at day 3, 7 and 14 could predict poor func-
tional outcome at day 90 in CE patients (Figure 5A). In
contrast, higher VEGF values tended to predict good
functional outcome in ATBI patients, although they did
not reach statistical significance (Figure 5B).Figure 5 Significance of plasma VEGF values in prediction of function
per 100 pg/mL increase in VEGF values at the indicated days after ischemic
gender, hypertension, diabetes mellitus, neurological severity (NIHSS at dayDiscussion
In the present study, we demonstrated that 1) plasma
VEGF values increased immediately after the onset, and
the increase in VEGF values lasted for at least 90 days in
all stroke subtypes, and 2) the clinical significance of
plasma VEGF value in neurological severity and func-
tional outcome was different among stroke subtypes.
Higher plasma VEGF values may be a predictor of pooral outcome. Multivariate-adjusted odds ratio for functional outcome
stroke in CE (A) and ATBI (B). The multivariate model included age,
0) and thrombolytic therapy. OR: odds ratio, CI: confidence interval.
Matsuo et al. BMC Neurology 2013, 13:32 Page 7 of 8
http://www.biomedcentral.com/1471-2377/13/32functional outcome in CE patients, while the opposite
trend was found in ATBI patients.
Consistent with the present study, previous reports
showed that serum VEGF value is increased in human
stroke patients [10,11]. They demonstrated simply that the
serum VEGF levels were correlated with infarct volume and
neurological severity. The differences between our study and
the previous one are that 1) plasma VEGF values increase
in all stroke subtypes, 2) the increase of VEGF values
lasts for 3 months in all subtypes, and 3) clinical signifi-
cance of plasma VEGF values differs among stroke
subtypes.
Plasma VEGF value increases in all stroke subtypes
In the present study, plasma VEGF values were signifi-
cantly higher in all stroke subtypes than those of the
controls throughout the observation period (= 90 days)
(Figure 2A-2D). Animal stroke models elucidated that
the expression of VEGF is upregulated particularly in
the ischemic penumbra [7,19,20]. Although we could
not explain the reasons why plasma VEGF values were
equally increased in all stroke subtypes, one possibility is
that penumbral volumes may be similar even if necrotic
volumes are different. Alternatively, humoral factors that
are leaked or released from ischemic cells may diffuse
into penumbral areas and equally induce the expression
of VEGF regardless of infarct size. Another interesting
finding of this study is that the increase in plasma VEGF
value lasted for a longer period than we expected after
the stroke onset in all stroke subtypes. A previous report
showed that serum VEGF levels were higher in both
the acute and chronic phases in the large vessel disease
and only in the acute phase in the small vessel disease,
compared with control. They concluded that increased
serum VEGF levels might contribute to neurological im-
provement after 3 months [11]. The differences between
our study and the previous one were that 1) we did not
measure infarct volume, and 2) we used the plasma, but
not serum, for VEGF measurement [17], although we do
not know whether these differences affected the results.
Our observation suggests that the angiogenic response
leading to neuronal regeneration continues at least for
3 months. Although hypoxia-inducible factors are well-
characterized transcription factors that upregulate VEGF,
[21] hypoxia itself may not continue for 3 months. Because
VEGF plays a critical role in angiogenesis and neuronal re-
generation after ischemic stroke, [22] further investigation
is needed to elucidate the mechanisms underlying the pro-
longed production of VEGF irrespective of stroke subtypes.
Clinical significance of VEGF value differs among stroke
subtypes
Although plasma VEGF value was increased equally in
all stroke subtypes, its clinical significance may be quitedifferent among the subtypes. Plasma VEGF value was
positively correlated with neurological severity in CE pa-
tients, whereas the opposite trend was observed in ATBI
patients. LAC showed the similarity to CE rather than
ATBI in terms of the association between VEGF values
and functional outcome (Figure 3). A previous report
showed that serum VEGF levels in the acute phase were
significantly associated with the long-term prognosis of
small and large vessel diseases, namely LAC and ATBI
[11], which was partially consistent with our study.
In chronic and weak cerebral hypoxia in the patients
with stenosis of the large cerebral arteries, VEGF may be
increased already before stroke onset and function as an
angiogenic [3] and neuroprotective molecule[6]. Thus,
higher VEGF values would attenuate neuronal death and
reduce infarct volume in ATBI. On the other hand, se-
vere ischemia abruptly occurs without the absence of
collateral circulation in CE, and thus VEGF values at the
onset may simply reflect the intensity of ischemic dam-
age in CE patients. In addition, a rapid increase in VEGF
may increase the permeability of the blood–brain barrier,
thereby worsening cerebral edema rather than functio-
ning as a neuroprotective factor, as demonstrated in
experimental stroke models [8,9]. Although VEGF can
function as a neuroprotective and angiogenic molecule
leading to neuronal regeneration, higher VEGF value in
CE in the acute phase may rather associate with the se-
verity of ischemic damage, thereby predicting poor func-
tional outcome in CE patients. In terms of the abrupt
ischemia and the absence of collateral circulation, LAC
may be similar to CE rather than ATBI. Thus, the sig-
nificance of plasma VEGF value in functional outcome
in LAC may be similar to that of CE.
Limitation
One of the limitations of this study is the small sample
size. Further studies will be required to confirm the
subtype-dependent clinical significance of VEGF suggested
in the present study. Second limitation is the difference of
risk factors between control and patients, although there
was no association between VEGF values and risk factors.
Third one is the lack of measurement of infarct volume in
stroke patients. We used the NIHSS as an indicator of
neurological severity instead of infarct volume.
Conclusions
In conclusion, VEGF is increased in plasma immediately
after the stroke onset in all stroke subtypes. The increase
in plasma VEGF value continues for at least 90 days
after the onset regardless of stroke subtype. Although
it is established that VEGF plays important roles in
neuronal survival and angiogenesis leading to neuronal re-
generation, the clinical significance of plasma VEGF value
may be different among the stroke subtypes.
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Additional file 1: Table S1. Background characteristics of controls and
cases in each stroke subtype. Table S2. Association with VEGF values and
neurological severity in each stroke subtype at day 0 (A) and at day 14 (B).
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